Avastin (bevacizumab) • Tecentriq (atezolizumab) • pegylated liposomal doxorubicin • Myocet (non-pegylated liposomal doxorubicin) • doxorubicin liposomal

almost5years

Normalizing the Microenvironment Overcomes Vessel Compression and Resistance to Nano-immunotherapy in Breast Cancer Lung Metastasis. (PubMed, Adv Sci (Weinh))

Nano-immunotherapy regimens have high potential to improve patient outcomes, as already demonstrated in advanced triple negative breast cancer with nanoparticle albumin-bound paclitaxel and the immune checkpoint blocker (ICB) atezolizumab. Indeed, when combining tranilast with Doxil and ICBs, synergistic effects on efficacy, with all mice cured in one of the two ICB-insensitive tumor models investigated is resulted. These results suggest that strategies to treat breast cancer with nano-immunotherapy should also include a mechanotherapeutic to decompress vessels.

almost 5 years ago

Journal

ALB (Albumin)

Tecentriq (atezolizumab) • albumin-bound paclitaxel • doxorubicin liposomal

almost5years

Coexistence of disseminated Kaposi sarcoma and multicentric Castleman disease in an HIV-infected patient under viral suppression. (PubMed, Int J STD AIDS)

A 46-year-old man had been diagnosed with HIV infection and treated with combination antiretroviral therapy of dolutegravir/abacavir/lamivudine (Triumeq) for one year. The plasma Kaposi sarcoma herpesvirus viral load was 365,000 copies/mL. During hospitalization, progressive pancytopenia and spiking fever persisted, and he died of multi-organ failure before completion of chemotherapeutic treatments with rituximab plus liposomal doxorubicin.

almost 5 years ago

Clinical • Journal

CD4 (CD4 Molecule)

Rituxan (rituximab) • doxorubicin liposomal

almost5years

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents (clinicaltrials.gov)

P2, N=164, Not yet recruiting, National Cancer Institute (NCI)

almost 5 years ago

Clinical • New P2 trial • Combination therapy

PD-L1 (Programmed death ligand 1) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset)

BRCA2 mutation • BRCA1 mutation • BRCA mutation

Avastin (bevacizumab) • Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel • pegylated liposomal doxorubicin • topotecan • Recentin (cediranib) • Myocet (non-pegylated liposomal doxorubicin) • doxorubicin liposomal

almost5years

Enhancing TNBC Chemo-immunotherapy via combination reprogramming tumor immune microenvironment with Immunogenic Cell Death. (PubMed, Int J Pharm)

The combination treatment led to trigger immunogenic tumor apoptosis, and enhance antitumor immunity, therefore, improved anti-tumor efficiency, and further prolonged survival duration. The combination of liposomal silybin and liposomal doxorubicin might be a new chemo-immunotherapy approach for triple negative breast cancer (TNBC) tumor treatment.

almost 5 years ago

Journal

IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CXCL12 (C-X-C Motif Chemokine Ligand 12) • TGFB1 (Transforming Growth Factor Beta 1)

IFNG elevation

doxorubicin liposomal

almost5years

Comparison of efficacy, safety, patients' quality of life, and doctors' occupational stress between lenalidomide-based and bortezomib-based induction in patients with newly diagnosed multiple myeloma. (PubMed, Cancer Med)

Compared to PAD, RAD induction had comparable efficacy and a significantly better safety profile, improved quality of life for patients, and reduced occupational stress for doctors. However, RAD induction may need to be limited to four cycles to avoid irreversible damage to hematopoietic stem cells.

almost 5 years ago

Clinical • Journal • HEOR

CD34 (CD34 molecule)

lenalidomide • bortezomib • doxorubicin liposomal

almost5years

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov)

P2, N=95, Active, not recruiting, AstraZeneca | Trial completion date: Mar 2021 --> Nov 2021

almost 5 years ago

Clinical • Trial completion date

CYP1A2 (Cytochrome P450, family 1, subfamily A, polypeptide 2)

carboplatin • gemcitabine • paclitaxel • adavosertib (AZD1775) • doxorubicin liposomal

almost5years

ARC-2: A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies (clinicaltrials.gov)

P1, N=214, Active, not recruiting, Arcus Biosciences, Inc. | Recruiting --> Active, not recruiting

almost 5 years ago

Clinical • Enrollment closed

HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)

HER-2 negative • ER negative • PGR negative

albumin-bound paclitaxel • pegylated liposomal doxorubicin • eganelisib (IPI-549) • etrumadenant (AB928) • doxorubicin liposomal

almost5years

EPIK-O: Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected (clinicaltrials.gov)

P3, N=326, Not yet recruiting, Novartis Pharmaceuticals

almost 5 years ago

Clinical • New P3 trial • Combination therapy

BRCA (Breast cancer early onset)

Lynparza (olaparib) • paclitaxel • Piqray (alpelisib) • pegylated liposomal doxorubicin • doxorubicin liposomal

almost5years

ATALANTE: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab (clinicaltrials.gov)

P3, N=614, Active, not recruiting, ARCAGY/ GINECO GROUP | Trial completion date: Sep 2023 --> Sep 2024 | Trial primary completion date: Jun 2021 --> Oct 2021

almost 5 years ago

Clinical • Trial completion date • Trial primary completion date

PD-L1 (Programmed death ligand 1)

Avastin (bevacizumab) • Tecentriq (atezolizumab) • paclitaxel • doxorubicin liposomal

almost5years

MIROVA: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer (clinicaltrials.gov)

P2, N=136, Not yet recruiting, AGO Research GmbH | Initiation date: Jul 2020 --> Jul 2021

almost 5 years ago

Clinical • Trial initiation date

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • FOLR1 ( Folate receptor alpha ) • MUC16 (Mucin 16, Cell Surface Associated)

BRCA2 mutation • BRCA1 mutation

carboplatin • gemcitabine • paclitaxel • pegylated liposomal doxorubicin • Elahere (mirvetuximab soravtansine-gynx) • doxorubicin liposomal

almost5years

Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity. (PubMed, J Nanobiotechnology)

Our results indicate that this "double-attack" strategy using CD20 Ab-mPEG scFv and PLD can retain the tumor targeting (first attack) and confer PLD tumor-selectivity (second attack) to enhance PLD internalization and improve therapeutic efficacy in liquid tumors.

almost 5 years ago

Journal

CD20 (Membrane Spanning 4-Domains A1)

Arzerra (ofatumumab) • doxorubicin liposomal